Please assess the completion status of the following clinical trial:

Trial Title: Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Clinical diagnosis of unstable angina or non ST-elevation myocardial infarction, and requiring clinically indicated PCI for the management of non ST elevation acute coronary syndrome.~Exclusion Criteria:~* Systemic hypotension (systolic \<90 mmHg)~* Heart failure or known ejection fraction \< 30%~* Left main disease~* Culprit lesion is in a saphenous vein graft~* 100% occlusion of the culprit vessel or culprit is an ostial right coronary stenosis~* Currently enrolled in other active cardiovascular investigational studies~* Severe endocrine, hepatic, or renal disorders~* Pregnancy or lactation~* Federal Medical Center inmates~* Inability or unwillingness to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BQ-123 (Type: EXPERIMENTAL): BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
- Placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.

Based on this trial design, predict the completion outcome and termination type (if applicable).